|
14.Peet MM, Isberg EM. The surgical treatment of essential hypertension. J Am Med Assoc 1946; 130:467–473.
15.Smithwick RH. Surgical treatment of hypertension. Am J Med 1948; 4:744–759.
16.Grimson KS. Total thoracic and partial to total lumbar sympathectomy and celiac ganglionectomy in the treatment of hypertension. Ann Surg 1941; 114:753–775.
17.Esler M, Jennings G, Biviano B, Lambert G, Hasking G. Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol 1986; 8 Suppl 5:S39–S43.
18.Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G,Hastings J, Aggarwal A, Esler MD. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension 2004; 43:169–175.
19.Ye S, Gamburd M, Mozayeni P, Koss M, Campese VM. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 1998;11:723–728.
20.Ye S, Zhong H, Yanamadala V, Campese VM. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 2002; 15:717–724.
21.Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure.Hypertension 1995; 25:878–882.
22.Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 1995; 26:861–865.
23.Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361:932–934.
24.Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B,Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373:1275–1281.
25.Symplicity HTN-1 Investigators. Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: Durability of Blood Pressure Reduction Out to 24 Months Hypertension. 2011;57:911-917
26.Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903–1909.
27.Hansen JM, Abildgaard U, Fogh-Andersen N, Kanstrup IL, Bratholm P, Plum I,Strandgaard S. The transplanted human kidney does not achieve functional reinnervation. Clin Sci 1994; 87:13–20.
28.Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361:932–934.
29.Felix Mahfoud, Markus Schlaich, Ingrid Kindermann, Christian Ukena, Bodo Cremers, Mathias C. Brandt, Uta C. Hoppe, Oliver Vonend, Lars C. Rump, Paul A. Sobotka, Henry Krum, Murray Esler, and Michael Böhm. Response to Letter Regarding Article, “Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension: A Pilot Study” Circulation. 2011;124:e537
30.Schlaich, Markus P; Straznicky, Nora; Grima, Mariee; Ika-Sari, Carolina; Dawood, Tye; Mahfoud, Felix; Lambert, Elisabeth; Chopra, Reena; Socratous, Flora; Hennebry, Sarah; Eikelis, Nina; Böhm, Michael; Krum, Henry; Lambert, Gavin; Esler, Murray D; Sobotka, Paul A Renal denervation: a potential new treatment modality for polycystic ovary syndrome? Journal of Hypertension. 29(5):991-996, May 2011 |